Premium
Bone marrow aplasia—a rare complication of imatinib therapy in CML patients
Author(s) -
Srinivas Upendra,
Pillai Lakshmi S.,
Kumar Rajat,
Pati H.P.,
Saxena Renu
Publication year - 2007
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20776
Subject(s) - bone marrow aplasia , medicine , imatinib , aplasia , imatinib mesylate , bone marrow , complication , adverse effect , anemia , aplastic anemia , surgery , myeloid leukemia
Imatinib mesylate therapy in CML patients is a generally well tolerated without any significant hematological adverse drug effects. However, complications like anemia and cytopenias have been described in literature. A very few case reports of bone marrow aplasia following imatinib therapy have been reported so far. We here report five patients of CML who developed bone marrow aplasia following imatinib therapy. Am. J. Hematol., 2006. © 2006 Wiley‐Liss, Inc.